When phenotyping circulating tumor-specific T cells following dual therapy, we observed small but significant increases in the level of PD-1 expression at day 14 following therapy (see also Supplementary Fig. 8a), suggesting that at least some of these circulating T cells have proliferated and/or recently encountered antigen. Here, PDCD1 is linked to neoplasm.